Viking Therapeutics' VK2735 has reported up to 14.7% mean weight reduction at 13 weeks in the VENTURE Phase 2 trial, with the Phase 3 VANQUISH program now fully enrolled.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.